All In Biotech

Drug Trial Radar · NCT07576959

Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication

Effect of Bismuth Add-on to Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Eradication - A Multicenter Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 990 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

990

Planned (sponsor's estimate)

Start

Apr 8, 2026

Primary completion

Dec 31, 2030

Study completion Dec 31, 2032

Sponsor

Lead sponsor
National Taiwan University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based dual therapy ( triple therapy) versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication. Furthermore, the investigators will investigate the impact of these eradication regimens on the gut microbiota, the development of antibiotic resistance, and changes in metabolic syndrome indicators pre- and post-treatment.

Conditions

  • HELICOBACTER PYLORI INFECTIONS

Interventions

  • Bismuth Add-on to Vonoprazan Dual TherapyDrug

    bismuth, vonoprazan and amoxicillin for 14 days

  • Vonoprazan dual therapyDrug

    vonoprazan and amoxicillin for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication rate determined by Intention-to-Treat (ITT) analysisTime frame: 6-8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.